Indication intelligence, analysis and sector perception

Capricor (CAPR) Licenses additional patent applications from Cedars-Sinai Medical Center (CSMC) for cellular and exosome-based technologies

January 16, 2018 7:49am

Pre-market, CAPR is UP +$0.15 or +8.43% - tell the real story! Think the CEO got a good deal from her :husband’s" CSMC lab, the additional cost to the research agreement is what and who is paying for the filings - CAPR!

Capricor Therapeutics (CAPR) has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles, including exosomes.

The Exclusive License Agreements with Cedars-Sinai grant Capricor exclusive worldwide rights to commercially develop and market CDCs, which comprise Capricor’s lead investigational cell therapy, CAP-1002, as well as CDC-derived exosomes, which comprise its lead investigational exosome-based therapy candidate, CAP-2003.

The new patent applications expand the scope of the Exclusive License Agreements to enable Capricor to develop new therapeutic indications for its cellular and exosome therapies in Duchenne muscular dystrophy, ventricular tachyarrhythmia, cancer and age-related disorders.

“Obtaining the rights to these additional patent applications will expand and potentially strengthen Capricor’s intellectual property portfolio.”

What are the additional costs of licenses to the Cedars-Sinai Medical Center?

Pre-market, CAPR is UP +$0.15 or +8.43% - tell the real story!

... SELL ...

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 42 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.